Business Wire Feed

Biomunex Announces Strategic Artificial Intelligence Collaborations to Further Accelerate the Discovery and Development Processes of Its Innovative Pipeline of Cancer Immunotherapies

May 26th, 2026|

Collaborations with Gordion Bioscience and Tangramed Biotech, two AI-specialized companies, further strengthen Biomunex's integration of artificial intelligence (AI) into its R&D activities and support the development of next generation immunotherapies in oncologyPARIS & CAMBRIDGE, Mass.--(BUSINESS more...

Inocras Announces ASCO 2026 Online Publication: Whole-genome HRD phenotyping as a predictor of PARP inhibitor benefit in first-line maintenance high-grade serous ovarian cancer

May 22nd, 2026|

Study conducted with Severance Hospital shows whole-genome sequencing-based HRD phenotyping was associated with longer progression-free survival in patients receiving PARP inhibitor maintenance therapySAN DIEGO & SEOUL, South Korea--(BUSINESS WIRE)--#CancerGenome--Inocras, a bioinformatics-led company harnessing the power more...

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

May 22nd, 2026|

AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with an unprecedented median overall survival of approximately two years based on the TROPION-Breast02 more...

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.